Clinical utility of the guidelines for intraductal papillary mucinous neoplasm: A case series from a medical center in central Taiwan

Surgical resection is recommended for potential malignant or known malignant mucinous cystic neoplasm and intraductal papillary mucinous neoplasm (IPMN). The 2012 updated consensus guidelines proposed “high‐risk stigmata” and “worrisome features” as clinical predictors of malignancy. We present a series of six patients who were diagnosed with IPMN and evaluate the clinical utility of the 2006 and 2012 consensus guidelines with respect to treatment. By comparing the findings of imaging, dysplastic grade of IPMN, and disease outcomes, the dysplastic grade of the IPMN appears to be the most important predictor of patient outcomes. Disease recurrence with low‐to‐intermediate grade of IPMN is uncommon and affected only one of our patients. In summary, the application of the updated 2012 consensus guidelines and the precise assessment of the dysplastic grade and morphological type of IPMN before surgery could provide useful information for clinical disease management.